Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Imagem de Miniatura
Arquivos
art_BROSE_Cabozantinib_for_radioiodinerefractory_differentiated_thyroid_cancer_COSMIC311_a_2021.PDF (806.78 KB)
Citações na Scopus
128
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BROSE, Marcia S.
ROBINSON, Bruce
I, Steven Sherman
KRAJEWSKA, Jolanta
LIN, Chia-Chi
VAISMAN, Fernanda
HITRE, Erika
BOWLES, Daniel W.
HERNANDO, Jorge
Citação
LANCET ONCOLOGY, v.22, n.8, p.1126-1138, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have aggressive disease and no available standard of care. The aim of this study was to evaluate the tyrosine kinase inhibitor cabozantinib in this patient population. Methods In this global, randomised, double-blind, placebo-controlled, phase 3 trial, patients aged 16 years and older with radioiodine-refractory DTC (papillary or follicular and their variants) and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (2:1) to oral cabozantinib (60 mg once daily) or matching placebo, stratified by previous lenvatinib treatment and age. The randomisation scheme used stratified permuted blocks of block size six and an interactive voice-web response system; both patients and investigators were masked to study treatment. Patients must have received previous lenvatinib or sorafenib and progressed during or after treatment with up to two VEGFR tyrosine kinase inhibitors. Patients receiving placebo could cross over to open-label cabozantinib on disease progression confirmed by blinded independent radiology committee (BIRC). The primary endpoints were objective response rate (confirmed response per Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) in the first 100 randomly assigned patients (objective response rate intention-to-treat [OITT] population) and progression-free survival (time to earlier of disease progression per RECIST version 1.1 or death) in all patients (intention-to-treat [ITT] population), both assessed by BIRC. This report presents the primary objective response rate analysis and a concurrent preplanned interim progression-free survival analysis. The study is registered with ClinicalTrials.gov, NCT03690388, and is no longer enrolling patients. Findings Between Feb 27, 2019, and Aug 18, 2020, 227 patients were assessed for eligibility, of whom 187 were enrolled from 164 clinics in 25 countries and randomly assigned to cabozantinib (n=125) or placebo (n=62). At data cutoff (Aug 19, 2020) for the primary objective response rate and interim progression-free survival analyses, median followup was 6middot2 months (IQR 3middot4-9middot2) for the ITT population and 8middot9 months (7middot1-10middot5) for the OITT population. An objective response in the OITT population was achieved in ten (15%; 99% CI 5middot8-29middot3) of 67 patients in the cabozantinib group versus 0 (0%; 0-14middot8) of 33 in the placebo (p=0middot028) but did not meet the prespecified significance level (alpha=0middot01). At interim analysis, the primary endpoint of progression-free survival was met in the ITT population; cabozantinib showed significant improvement in progression-free survival over placebo: median not reached (96% CI 5middot7-not estimable [NE]) versus 1middot9 months (1middot8-3middot6); hazard ratio 0middot22 (96% CI 0middot13-0middot36; p<0middot0001). Grade 3 or 4 adverse events occurred in 71 (57%) of 125 patients receiving cabozantinib and 16 (26%) of 62 receiving placebo, the most frequent of which were palmar-plantar erythrodysaesthesia (13 [10%] vs 0), hypertension (11 [9%] vs 2 [3%]), and fatigue (ten [8%] vs 0). Serious treatment-related adverse events occurred in 20 (16%) of 125 patients in the cabozantinib group and one (2%) of 62 in the placebo group. There were no treatment-related deaths. Interpretation Our results show that cabozantinib significantly prolongs progression-free survival and might provide a new treatment option for patients with radioiodine-refractory DTC who have no available standard of care.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/42444
Referências
  1. Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
  2. Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186
  3. Babu G, 2021, MOL CLIN ONCOL, V14, DOI 10.3892/mco.2020.2197
  4. Brose MS, 2019, CLIN CANCER RES, V25, P7370, DOI 10.1158/1078-0432.CCR-18-3439
  5. Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
  6. Brose MS, 2018, P AM SOC CLIN ONCOL, V36
  7. Cabanillas ME, 2017, J CLIN ONCOL, V35, P3315, DOI 10.1200/JCO.2017.73.0226
  8. Cabanillas ME, 2014, THYROID, V24, P1508, DOI 10.1089/thy.2014.0125
  9. Cancer Stat Facts SEER, THYR CANC THYR CANC
  10. Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3
  11. Collina F, 2019, CANCERS, V11, DOI 10.3390/cancers11060785
  12. Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838
  13. Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
  14. Ferrari SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00176
  15. Fleeman N, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6369-7
  16. Fugazzola L, 2019, EUR THYROID J, V8, P227, DOI 10.1159/000502229
  17. Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
  18. Kish JK, 2020, ADV THER, V37, P2841, DOI 10.1007/s12325-020-01362-6
  19. Lirov R, 2017, DRUGS, V77, P733, DOI 10.1007/s40265-017-0733-1
  20. Narayanan S, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0404-6
  21. National Comprehensive Cancer Network, 2020, CLIN PRACTICE GUIDEL
  22. Oh HS, 2019, THYROID, V29, P1804, DOI 10.1089/thy.2019.0246
  23. Prescott JD, 2015, CANCER-AM CANCER SOC, V121, P2137, DOI 10.1002/cncr.29044
  24. Ruco L, 2014, BIOMEDICINES, V2, P263, DOI 10.3390/biomedicines2040263
  25. Salvatore D, 2021, NAT REV ENDOCRINOL, V17, P296, DOI 10.1038/s41574-021-00470-9
  26. Schlumberger M, 2021, NAT REV ENDOCRINOL, V17, P176, DOI 10.1038/s41574-020-00448-z
  27. Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
  28. Schmidbauer B, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061292
  29. Schoumacher M, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0579-4
  30. Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240
  31. Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489
  32. Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264
  33. Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343
  34. Zhu CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1090-3

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03